ROIV (STOCKS)
Roivant Sciences Ltd. Common Shares
$36.200000
-0.080000 (-0.22%)
Prev close: $36.280000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Matthew Gline
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $26,140.87M
- Employees
- 750
- P/E (TTM)
- -82.54
- P/B (TTM)
- 6.18
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
9
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q1)
|
$-0.26 | $-0.34 | +0.0760 | +22.62% |
|
Mar 2026 (Q4)
|
$-0.58 | $-0.35 | -0.2277 | -64.63% |
|
Dec 2025 (Q3)
|
$-0.38 | $-0.32 | -0.0560 | -17.28% |
|
Sep 2025 (Q2)
|
$-0.17 | $-0.34 | +0.1710 | +50.15% |
Financial Statements
| Revenues | $7.53M |
| Benefits Costs and Expenses | $297.41M |
| Costs And Expenses | $297.41M |
| Operating Expenses | $1.37B |
| Research and Development | $730.91M |
| Other Operating Expenses | $643.39M |
| Operating Income/Loss | -$596.14M |
| Income/Loss From Continuing Operations After Tax | -$414.60M |
| Income/Loss From Continuing Operations Before Tax | -$289.88M |
| Income Tax Expense/Benefit | $124.72M |
| Net Income/Loss | -$414.60M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$148.35M |
| Net Income/Loss Attributable To Parent | -$266.25M |
| Net Income/Loss Available To Common Stockholders, Basic | -$318.77M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.36 |
| Diluted Earnings Per Share | -$0.47 |
| Basic Average Shares | 2,106,396,438 |
| Diluted Average Shares | 2,106,396,438 |
| Assets | $5.31B |
| Current Assets | $4.74B |
| Cash | $3.80B |
| Other Current Assets | $942.08M |
| Noncurrent Assets | $564.41M |
| Fixed Assets | $11.32M |
| Other Non-current Assets | $553.09M |
| Liabilities | $384.62M |
| Current Liabilities | $283.60M |
| Accounts Payable | $25.08M |
| Wages | $40.82M |
| Other Current Liabilities | $217.70M |
| Noncurrent Liabilities | $101.02M |
| Equity | $4.92B |
| Equity Attributable To Noncontrolling Interest | $690.60M |
| Equity Attributable To Parent | $4.23B |
| Liabilities And Equity | $5.31B |
| Net Cash Flow From Operating Activities | -$816.47M |
| Net Cash Flow From Operating Activities, Continuing | -$816.47M |
| Net Cash Flow From Investing Activities | $684.64M |
| Net Cash Flow From Investing Activities, Continuing | $684.64M |
| Net Cash Flow From Financing Activities | $140.49M |
| Net Cash Flow From Financing Activities, Continuing | $140.49M |
| Net Cash Flow | $8.67M |
| Net Cash Flow, Continuing | $8.67M |
| Comprehensive Income/Loss | -$432.83M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | -$150.15M |
| Comprehensive Income/Loss Attributable To Parent | -$282.69M |
| Other Comprehensive Income/Loss | -$18.23M |